Pulmonx (LUNG) Liabilities and Shareholders Equity (2019 - 2025)

Pulmonx (LUNG) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $129.3 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 20.61% year-over-year to $129.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $565.5 million (down 15.28% YoY) and the FY2025 annual result came in at $129.3 million, down 20.61% from the prior year.
• Liabilities and Shareholders Equity slipped to $129.3 million in Q4 2025 per LUNG's latest filing, from $138.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $255.3 million in Q1 2021 and bottomed at $129.3 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $189.1 million (2023), against an average of $190.4 million.
• The widest annual swing landed in 2021, when Liabilities and Shareholders Equity surged 246.44%; it then retreated 20.61% in 2025.
• Tracing LUNG's Liabilities and Shareholders Equity over 5 years: stood at $235.2 million in 2021, then decreased by 17.65% to $193.7 million in 2022, then declined by 8.21% to $177.8 million in 2023, then retreated by 8.4% to $162.8 million in 2024, then dropped by 20.61% to $129.3 million in 2025.
• Per Business Quant, the three latest LUNG Liabilities and Shareholders Equity figures stand at $129.3 million (Q4 2025), $138.3 million (Q3 2025), and $147.2 million (Q2 2025).

Peer Comparison